Treatment in esophagogastric junction cancer: Past, present and future.


Servicio Oncología Médica, Hospital de Sabadell-Corporació Sanitària Parc Taulí, Sabadell, Barcelona, España. Electronic address: [Email]


Adenocarcinomas of the gastroesophageal junction represent 27% of all gastric tumors. n recent years, it has been classified as an entity of its own, with specific treatments that are sometimes differentiated from gastric treatments. Treatment can be based on chemotherapy (CTx) or chemoradiotherapy (CRTx) that is administered preoperatively (neoadjuvant), postoperatively (adjuvant) or perioperatively. There are studies that have tested several treatment modalities, but there is currently no single protocolized sequence. The results point to an improvement in survival when we administer preoperative treatment, with evidence in favor of CRTx and CTx. Studies are already underway with targeted treatment that aim to increase the activity of traditional chemotherapy. In the next few years, we should know the role of immunotherapy in this group of patients.


Adjuvant treatment,Cáncer de la unión esofagogástrica,Cáncer gástrico,Gastric cancer,Gastroesophageal junction cancer,Neoadjuvant treatment,Perioperative treatment,Tratamiento adyuvante,Tratamiento neoadyuvante,Tratamiento perioperatorio,